Overview

Eszopiclone for the Treatment of Posttraumatic Stress Disorder

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if eszopiclone relative to placebo (sugar pill) is effective and tolerable for people with posttraumatic stress disorder (PTSD)-related sleep disturbance. The investigators will also examine the impact of treatment on sleep patterns, memory recall bias, and level of inflammatory markers (cytokines). The investigators predict eszopiclone will lead to greater improvement than placebo in measures of PTSD symptoms, memory recall bias, and level of inflammatory markers.
Phase:
Phase 4
Details
Lead Sponsor:
Rush University Medical Center
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Eszopiclone